SecBot SecBot
PRESS-RELEASE ·Filed Jun 15, 2026

RYTM

Rhythm Pharmaceuticals, Inc.
BULLISH
Impact 6/10
Horizonweeks Processed5mo ago WireGlobeNewswire
Press release · M&A
Actionable Insight ▲ Bullish

The data reinforces setmelanotide's efficacy across multiple rare obesity indications, supporting revenue growth trajectory. Monitor upcoming regulatory milestones for bivamelagon and PWS expansion. The stock has limited near-term catalyst beyond these data; long-term holders should watch for label expansion updates and quarterly sales figures.

DirectionBullish
Confidencemedium
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$89.72
T+0 close · Jun 15, 2026 · via day close
Latest settled
+13.91%
T+60 · $102.20
Vs SPY
+12.91%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 16 $89.72entry
  2. T+1 · 5mo ago +6.81%α +8.06% · $95.83
  3. T+5 · 5mo ago +18.36%α +20.59% · $106.19
  4. T+20 · 4mo ago +22.56%α +22.36% · $109.96
  5. T+60 · 2mo ago +13.91%α +12.91% · $102.20
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Rhythm Pharmaceuticals presented positive clinical and real-world data at ENDO 2026 for setmelanotide and bivamelagon across multiple rare obesity indications (acquired hypothalamic obesity, BBS, PWS). The data showed sustained weight loss, hunger reduction, and improved healthcare utilization, reinforcing the commercial thesis for its MC4R agonist platform. The stock market reaction is likely muted as the data is incremental and consistent with prior disclosures, but the breadth of positive readouts across indications supports the long-term pipeline value.

Key Facts

  • Setmelanotide achieved -18.9% mean BMI reduction at 2.5 years in acquired HO patients (n=11).
  • Oral bivamelagon showed -8.7% to -16.6% BMI reduction at 1 year across dose cohorts (n=26).
  • 71.1% of pediatric and 71.4% of adult acquired HO patients achieved ≥1 weight category improvement with setmelanotide vs 13.6% and 6.7% on placebo.
  • Real-world BBS data (n=286): 62% of adults achieved ≥10% body weight loss at 12 months; mean -9.8% weight loss in adults.
  • PWS Phase 2 six-month results announced June 13 (separate press release).
  • No new financial guidance, revenue, or EPS figures were disclosed.

Financial Impact

No financial figures disclosed; data supports continued commercial adoption and pipeline expansion for setmelanotide and bivamelagon.

revenuepipeline value

Risk Factors

  • Competition from other MC4R agonists and GLP-1 therapies for broader obesity.
  • Regulatory setbacks for bivamelagon or PWS indication.
  • Commercial execution risk for setmelanotide in acquired HO and BBS.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3312120

Track record

26 reports on RYTM

Performance horizon

8 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +32.06% at T+60 after the May 1, 2026 report. 10 of 13 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Bullish 5/10 Entry $107.48 Now $107.48 +0.00% settles Nov 24
  2. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
  3. Nov 4, 202612d ago Press Release Bullish 5/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
  4. Nov 3, 202613d ago 8-K Bullish 6/10 No price data
  5. Nov 3, 202613d ago Press Release Bullish 6/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
  6. Nov 2, 202614d ago Press Release Neutral 5/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
  7. Oct 13, 20264w ago Press Release Bullish 6/10 Entry $86.71 to $88.62 Now $107.48 +23.95% ▲ +2.20% +1.75% vs SPY
  8. Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $86.61 to $90.20 Now $107.48 +24.10% ▲ +4.14% +5.30% vs SPY
  9. Sep 14, 20269w ago 144 Bearish 5/10 Entry $96.77 to $99.27 Now $107.48 −11.07% ▼ −2.58% −0.47% vs SPY
  10. Aug 17, 202613w ago Insider Cluster Bearish 6/10 Entry $115.25 to $113.35 Now $107.48 +6.74% ▲ +1.65% +1.45% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens Wed (11h 21m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 15, 2026